TechBio Talks with Najat Khan and Morgan Cheatham

On last week’s episode of TechBio Talks, CEO of Recursion, Najat Khan and Morgan Cheatham, Partner and Head of Healthcare and Life Sciences at Breyer Capital connected for a conversation spanning biotech value creation, building data moats, and the future of medicine. They unpacked: 🎯 Collapsing target ID and early patient selection to treat the root biological cause 🧬 Unlocking decades of tissue and diagnostic data sitting in clinical biobanks 🩺 Extracting hidden knowledge and research-grade insights from the routine clinical data we already collect every day Catch up on their full conversation here: YouTube: https://youtu.be/LmVszrLN0cg?si=9_lXBKBj7eS5VxSY Spotify: https://open.spotify.com/episode/6BEkyyZjRitxHFj5lezZfQ?si=34c7c5ac7039465b Apple: https://podcasts.apple.com/us/podcast/techbio-talks-episode-6-breyer-capitals-morgan-cheatham/id1834770803?i=1000791496475